XEN45 Implant in Medically Controlled vs. Uncontrolled Eyes—Differential IOP Changes in Real-Life Conditions

Author:

Julio Gemma12ORCID,Larena Raquel12ORCID,Mármol Marta12,Soldevila Anna12,Canut María Isabel123,Pavan Josip4,Barraquer Rafael I.125

Affiliation:

1. Centro de Oftalmología Barraquer, 08021 Barcelona, Spain

2. Institut Universitari Barraquer, Universitat Autònoma de Catalunya, 08021 Barcelona, Spain

3. Clínica Oftalvist, 08017 Barcelona, Spain

4. Department of Ophthalmology, Dubrava University Hospital, 10000 Zagreb, Croatia

5. School of Medicine, Universitat Internacional de Catalunya, 08193 Barcelona, Spain

Abstract

Background: To assess intraocular pressure (IOP) changes and complications after XEN45 implants in medically controlled eyes (MCE) vs. medically uncontrolled eyes (MUE). Methods: A retrospective study, in a tertiary referral hospital, on mild-to-moderate primary open-angle glaucoma (POAG) cases under topical medication, including 32 eyes with IOP < 21 mmHg (MCE group) and 30 eyes with IOP ≥ 21 mmHg (MUE group). The success criteria using Kaplan–Meier analysis was IOP < 21 mmHg without medications (complete success) or fewer drugs than preoperatively (qualified success) at the last visit, without new surgery or unresolved hypotony. Results: No significant preoperative differences were found between the groups. The mean IOP was 15.6 ± 3.8 mmHg in MCE and 15.1 ± 4.1 mmHg in the MUE group (p > 0.05; Mann–Whitney test) at the end of the follow-up (mean of 26.1 ± 15.6 months and 28.3 ± 15.3 months, respectively) (p = 0.414, Mann–Whitney Test). The device caused a significant IOP reduction at 24 h in both groups. Thereafter, the MCE group significantly tended to increase IOP, recovering baseline values at 1 month and maintaining them until the end of the follow-up. In contrast, in the MUE group, the IOP values tended to be similar after the first reduction. No relevant complications and no significant differences between the groups in the survival analysis were found. Conclusions: XEN45 provided stable IOP control in both the MCE and MUE group without important complications in the medium term. The IOP increasing in the MCE group, after a prior decrease, led to restored baseline values 1 month after surgery. The homeostatic mechanism that causes the rise in the IOP to baseline values and its relationship with failure cases remains to be clarified.

Funder

Allergan, an AbbVie company

Publisher

MDPI AG

Reference45 articles.

1. Ocular Surface Evaluation in Eyes with Chronic Glaucoma on Long Term Topical Antiglaucoma Therapy;Saini;Int. J. Ophthalmol.,2017

2. Side Effects of Glaucoma Medications;Bull.-Soc. Belg. D Ophtalmol.,2006

3. XEN® Implant and Trabeculectomy Medium-Term Quality of Life Assessment and Comparison of Results;Passos;Int. J. Ophthalmol.,2018

4. Long-Term Morphologic Effects of Antiglaucoma Drugs on the Conjunctiva and Tenon’s Capsule in Glaucomatous Patients;Sherwood;Ophthalmology,1989

5. Global Data on Visual Impairment in the Year 2002;Resnikoff;Bull. World Health Organ.,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3